The upper gastrointestinal bleeding and transferrin TF (Changweile) independently developed by Linaxin Biotechnology ™） The home warning self-test kit has successfully obtained the national Class II medical device registration certificate (registration certificate number: Lu Qi Zhun Zhu: 20212401172) issued by the China Medical Products Administration. The acquisition of this registration certificate marks the approval of another upper gastrointestinal bleeding home warning self-test product for sale.

Linaxin Biotechnology is a technology-based enterprise specializing in home cancer early screening. It was jointly founded by leading talents, domestic and foreign biomedical PhDs, and gene sequencing scientists. The expert committee is composed of national Changjiang Scholars, professors, and clinical experts from tumor hospitals. Its wholly-owned subsidiary, Linaxin Nuokang (Shandong) Biomedical Technology Co., Ltd., has a phase one GMP production base of 1500 square meters with 100000 and 10000 levels, and has 5 internationally advanced cancer early screening and in vitro diagnostic kit production lines. We have jointly established a 1000 square meter Binzhou Yellow River Ballad Medical Laboratory with Binzhou Xinyue Rehabilitation Hospital, which has the testing capability to measure 500000 people annually.

After years of practice by the team, Linaxin Biotechnology has 15 independent intellectual property patents and has been honored as a leading technology enterprise in Kunshan, China's "Double Creation" initiative, the "Third Prize" in the Maker Paradise Industry Competition, the "Excellence Award" for Innovation Bridge and Employment Dreams, and an excellent entrepreneurial project in Jiangsu Province. In addition, Linaxin Biotechnology has reached strategic cooperation with Dian Diagnostics, Hunan Cancer Hospital/Xiangya Medical College Affiliated Cancer Hospital of Central South University, Jiangsu Traditional Chinese Medicine Hospital, Nanjing Medical University Affiliated Hospital, Guizhou Medical University Affiliated Hospital, Suqian First People's Hospital, Binzhou Xinyue Rehabilitation Hospital, national chain pharmacies, etc., to jointly promote early cancer screening! Let precise early screening enter thousands of households and break through the last mile of cancer early screening. Linaxin Biotechnology adheres to the mission of early screening of a sample, saving a life, benefiting a family, and improving people's health. It focuses on home, portable, and fast early cancer screening, and constantly introduces new products.

This product allows users to independently complete all operations at home, and can perfectly adapt to different usage scenarios such as hospitals, chain pharmacies, physical examination centers, health management centers, and home self testing. It also integrates fast, portable, painless, and non-invasive features, with results visible within 30 seconds. The launch of this product has provided the general public with higher-level and more convenient health examination services, making a positive contribution to the health industry.

Investment Hotline: 0512-57721793